Prolonged survival of mice with multiple liver metastases of human colon cancer by intravenous administration of replicable E1B-55K-deleted adenovirus with E1A expressed by CEA promoter

Molecular Therapy

Volumn 10, Issue 6, 2004, Pages 1043-1050

  Sagawa, Tamotsu ^a   Takahashi, Minoru ^a   Sato, Tsutomu ^a   Sato, Yasushi ^a   Lu, Yue ^a   Sumiyoshi, Tetsuya ^a   Yamada, Yasuyuki ^a   Iyama, Satoshi ^a   Fukaura, Junki ^a   Sasaki, Katsunori ^a   Hamada, Hirofumi ^a   Miyanishi, Koji ^a   Takayama, Tetsuji ^a   Kato, Junji ^a   Niitsu, Yoshiro ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CARCINOEMBRYONIC ANTIGEN; E1A PROTEIN; E1B PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER MODEL; CANCER REGRESSION; CANCER SURVIVAL; CELL STRAIN HT29; COLON CANCER; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; DRUG EFFICACY; FEMALE; GENE DELETION; HUMAN; HUMAN CELL; IN VITRO STUDY; INOCULATION; LIVER METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; NUDE MOUSE; PROMOTER REGION; PROTEIN EXPRESSION; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR XENOGRAFT; VIRUS REPLICATION;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; ADENOVIRUS E1B PROTEINS; ANIMALS; CARCINOEMBRYONIC ANTIGEN; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; GENE DELETION; GENE THERAPY; HEPATOCYTES; HUMANS; INFUSIONS, INTRAVENOUS; LIVER NEOPLASMS; MICE; NEOPLASM TRANSPLANTATION; PROMOTER REGIONS (GENETICS); SKIN NEOPLASMS; SURVIVAL RATE; TIME FACTORS; TUMOR CELLS, CULTURED; VIRUS REPLICATION;

ADENOVIRIDAE; MUS MUSCULUS;

EID: 10344223982     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2004.08.023     Document Type: Article

References (33)

1. K.E. Zavadsky Y.T. Lee Liver metastases from colorectal carcinoma: incidence, resectability, and survival results Am. Surg. 60 1994 929-933
2. H. Bismuth R. Adam F. Navarro D. Castaing L. Engerran A. Abascal Re-resection for colorectal liver metastasis Surg. Oncol. Clin. North Am. 5 1996 353-364
3. R. Midgley D. Kerr Colorectal cancer Lancet 353 1999 391-399
4. J.R. Bischoff et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells Science 274 1996 373-376
5. D.D. Barker A.J. Berk Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection Virology 156 1987 107-121
6. N.A. Habib et al. E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors Hum. Gene Ther. 12 2001 219-226
7. T. Reid et al. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: A phase I trial Gene Ther. 8 2001 1618-1626
8. T. Reid et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): Phase II viral, immunologic, and clinical endpoints Cancer Res. 62 2002 6070-6079
9. I. Ganly et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer Clin. Cancer Res. 6 2000 798-806
10. F.R. Khuri et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer Nat. Med. 6 2000 879-885
11. J. Nemunaitis et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial Cancer Res. 60 2000 6359-6366
12. J. Nemunaitis et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer J. Clin. Oncol. 19 2001 289-298
13. F.D. Goodrum D.A. Ornelles p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection J. Virol. 72 1998 9479-9490
14. T. Rothmann A. Hengstermann N.J. Whitaker M. Scheffner H. zur Hause Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells J. Virol. 72 1998 9470-9478
15. A.S. Turnell R.J. Grand P.H. Gallimore The replicative capacities of large E1B-null group A and group C adenoviruses are independent of host cell p53 status J. Virol. 73 1999 2074-2083
16. J.N. Harada A.J. Berk p53-independent and-dependent requirements for E1B-55K in adenovirus type 5 replication J. Virol. 73 1999 5333-5344
17. C.A. Richards E.A. Austin B.E. Huber Transcriptional regulatory sequences of carcinoembryonic antigen: Identification and use with cytosine deaminase for tumor-specific gene therapy Hum. Gene Ther. 6 1995 881-893
18. S. Pang et al. Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer Hum. Gene Ther. 6 1995 1417-1426
19. M. Takahashi et al. E1B-55K deleted adenovirus expressing E1A-13S by AFP-enhancer/promoter is capable of highly specific replication in AFP-producing hepatocellular carcinoma and eradication of established tumor Mol. Ther. 5 2002 627-634
20. M. Carpelan-Holmstrom C. Haglund P. Kuusela H. Jarvinen P.J. Roberts Preoperative serum levels of CEA and CA 242 in colorectal cancer Br. J. Cancer 71 1995 868-872
21. M.J. Duffy et al. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines Eur. J. Cancer 39 2003 718-727
22. N. Topf S. Worgall N.R. Hackett R.G. Crystal Regional 'pro-drug' gene therapy: Intravenous administration of an adenoviral vector expressing the E. coli cytosine deaminase gene and systemic administration of 5-fluorocytosine suppresses growth of hepatic metastasis of colon carcinoma Gene Ther. 5 1998 507-513
23. F.A. Nunes E.E. Furth J.M. Wilson S.E. Raper Gene transfer into the liver of nonhuman primates with E1-deleted recombinant adenoviral vectors: Safety of readministration Hum. Gene Ther. 10 1999 2515-2526
24. H. Tsuda et al. Efficient BMP2 gene transfer and bone formation of mesenchymal stem cells by a fiber-mutant adenoviral vector Mol. Ther. 7 2003 354-365
25. T. Nakamura K. Sato H. Hamada Reduction of natural adenovirus tropism to the liver by both ablation of fiber-coxsackievirus and adenovirus receptor interaction and use of replaceable short fiber J. Virol. 77 2003 2512-2521
26. H. Dehari et al. Enhanced antitumor effect of RGD fiber-modified adenovirus for gene therapy of oral cancer Cancer Gene Ther. 10 2003 75-85
27. P. Chen I. Kovesdi J.T. Bruder Effective repeat administration with adenovirus vectors to the muscle Gene Ther. 7 2000 587-595
28. H. Schrewe et al. Cloning of the complete gene for carcinoembryonic antigen: Analysis of its promoter indicates a region conveying cell type-specific expression Mol. Cell. Biol. 10 1990 2738-2748
29. M. Takahashi Y. Ilan N.R. Chowdhury J. Guida M. Horwitz J.R. Chowdhury Long term correction of bilirubin-UDP-glucuronosyltransferase deficiency in Gunn rats by administration of a recombinant adenovirus during the neonatal period J. Biol. Chem. 271 1996 26536-26542
30. Y. Sato et al. Enhanced and specific gene expression via tissue-specific production of Cre recombinase using adenovirus vector Biochem. Biophys. Res. Commun. 244 1998 455-462
31. T. Sato et al. An apoptosis-inducing gene therapy for pancreatic cancer with a combination of 55-kDa tumor necrosis factor (TNF) receptor gene transfection and mutein TNF administration Cancer Res. 58 1998 1677-1683
32. T. Igarashi S. Suzuki M. Takahashi T. Tamaoki T. Shimada A. novel strategy of cell targeting based on tissue-specific expression of the ecotropic retrovirus receptor gene Hum. Gene Ther. 9 1998 2691-2698
33. M. Yamamoto et al. Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer Gastroenterology 125 2003 1203-1218